Literature DB >> 14567019

The etiology, clinical presentation, and management of pseudomyxoma peritonei.

Brendan J Moran1, Thomas D Cecil.   

Abstract

PMP is a rare condition, which, although of "borderline malignancy," is invariably fatal. Difficulties exist with the definition of PMP. It has been broadly applied to include a heterogenous group of pathologic lesions that present clinically with "jelly belly" due to mucinous ascites. The relatively few reports in the literature commonly use different pathologic definitions, and there is no consensus on the point of separation between PMP and carcinomatosis secondary to a mucinous adenocarcinoma. Sugarbaker has suggested "the term pseudomyxoma peritonei syndrome be strictly applied to a pathologically and prognostically homogenous group of cases characterized by histologically benign peritoneal tumors that are frequently associated with an appendiceal mucinous adenoma." This definition excludes all cases with mucinous adenocarcinoma. The optimal treatment is undoubtedly complete tumor excision, by complex surgical peritonectomy procedures, taking on average 10 hours. Surgery is usually combined with intraperitoneal, and now intraoperative heated chemotherapy. These techniques have a high morbidity and mortality. The rarity of the condition, together with the risks associated with definitive treatment, suggests that such treatment ought to be centralized in a few centers, covering a large population. The search continues for safer, less aggressive treatments, but is hampered by a lack of hard evidence and the absence of experimental animal or human models to evaluate emerging strategies.

Entities:  

Mesh:

Year:  2003        PMID: 14567019     DOI: 10.1016/s1055-3207(03)00026-7

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  46 in total

1.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

2.  Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed.

Authors:  Irvin M Modlin; Mark Kidd; Igor Latich; Michelle N Zikusoka; Geeta N Eick; Shrikant M Mane; Robert L Camp
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

3.  High expression of RELP (Reg IV) in neoplastic goblet cells of appendiceal mucinous cystadenoma and pseudomyxoma peritonei.

Authors:  Kukka Heiskala; Jill Giles-Komar; Marja Heiskala; Leif C Andersson
Journal:  Virchows Arch       Date:  2005-12-02       Impact factor: 4.064

Review 4.  Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.

Authors:  Manuel J Koppe; Otto C Boerman; Wim J G Oyen; Robert P Bleichrodt
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 5.  Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A review of the literature.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu; Norihiro Kokudo; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2012-08

6.  Scalloping of the Liver.

Authors:  Ami Schattner; Jacob Gotler
Journal:  J Gen Intern Med       Date:  2015-12       Impact factor: 5.128

7.  Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry.

Authors:  Ai-Tao Guo; Xin Song; Li-Xin Wei; Po Zhao
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

8.  Pseudomyxoma peritonei: a rare cause of oliguric acute kidney injury.

Authors:  Hye Sook Min; Jeung Hui Pyo; Eul Sun Moon; Jonghyun Choi; Young Sun Kang; Mi Jin Lee; Jin Joo Cha; Dae Ryong Cha
Journal:  Chonnam Med J       Date:  2013-08-22

9.  Surgical management of carcinomatosis from colorectal cancer.

Authors:  Paul H Sugarbaker
Journal:  Clin Colon Rectal Surg       Date:  2005-08

Review 10.  Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancy.

Authors:  Erika Haase; Dal Yoo; Paul H Sugarbaker
Journal:  World J Surg Oncol       Date:  2009-05-19       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.